Generation Bio Co Market Cap ($35.98 Million)
Market Cap & Net Worth: Generation Bio Co (GBIO)
Generation Bio Co market cap. Generation Bio Co (NASDAQ:GBIO) has a market capitalization of $35.98 Million ($35.98 Million) as of November 5, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #22915 globally and #5036 in its home market, demonstrating a -4.81% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Generation Bio Co's stock price $5.34 by its total outstanding shares 6738545 (6.74 Million). Also see GBIO operating cash flow for how efficiently the company converts equity into cash flow.
Generation Bio Co Market Cap History (2020–2026)
Generation Bio Co market cap history from 2020 to 2026. Data shows change from $191.04 Million to $35.98 Million (-23.71% CAGR). Check GBIO stock price and chart for real-time trading data and today's change.
Index Memberships
Generation Bio Co is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.00% | #648 of 976 |
|
NASDAQ Composite
IXIC
|
$40.12 Trillion | 0.00% | #2152 of 3165 |
Weight: Generation Bio Co's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Generation Bio Co Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Generation Bio Co's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset momentum of Generation Bio Co to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.36x
Generation Bio Co's market cap is 0.36 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $26.48 Million | $880.00K | -$132.10 Million | 30.09x | N/A |
| 2023 | $11.12 Million | $5.90 Million | -$126.61 Million | 1.88x | N/A |
| 2024 | $7.14 Million | $19.89 Million | -$131.67 Million | 0.36x | N/A |
Competitor Companies of GBIO by Market Capitalization
Companies near Generation Bio Co in the global market cap rankings as of November 5, 2026. Also see Generation Bio Co total assets for a full breakdown of the balance sheet.
Key companies related to Generation Bio Co by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #181 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #373 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #415 globally with a market cap of $67.74 Billion USD ( AU$95.74 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #503 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #181 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $549.04 |
| #373 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $930.67 |
| #415 | CSL Ltd | AU:CSL | $67.74 Billion | AU$197.34 |
| #503 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $258.38 |
Market Capitalization of Generation Bio Co (2020–2026)
Market capitalization of Generation Bio Co from 2020 to today. Between 2020 and today, Generation Bio Co's market cap moved from $191.04 Million to $ 35.98 Million, with a yearly change of -23.71%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $35.98 Million | -5.99% |
| 2025 | $38.27 Million | +435.85% |
| 2024 | $7.14 Million | -35.76% |
| 2023 | $11.12 Million | -58.02% |
| 2022 | $26.48 Million | -44.49% |
| 2021 | $47.71 Million | -75.03% |
| 2020 | $191.04 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of Generation Bio Co was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $35.98 Million USD |
| MoneyControl | $35.98 Million USD |
| MarketWatch | $35.98 Million USD |
| marketcap.company | $35.98 Million USD |
| Reuters | $35.98 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Generation Bio Co
Generation Bio Co., a biotechnology company, discovers, develops, and commercializes redosable therapeutics that reprogram T cells in vivo to reduce or eliminate the production and persistence of autoreactive T cells. It develops cell-targeted lipid nanoparticles (ctLNP) to selectively deliver small interfering RNA (siRNA) T cells to selectively delivery, intracellular, and genetically precise me… Read more